Premium
Cellular expression of beta‐microseminoprotein (β‐MSP) mRNA and its protein in untreated prostate cancer
Author(s) -
Tsurusaki Toshifumi,
Koji Takehiko,
Sakai Hideki,
Kanetake Hiroshi,
Nakane Paul K.,
Saito Yutaka
Publication year - 1998
Publication title -
the prostate
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.295
H-Index - 123
eISSN - 1097-0045
pISSN - 0270-4137
DOI - 10.1002/(sici)1097-0045(19980501)35:2<109::aid-pros4>3.0.co;2-e
Subject(s) - immunohistochemistry , prostate cancer , prostate , in situ hybridization , messenger rna , pathology , beta (programming language) , cancer , medicine , pca3 , biology , cancer research , gene , biochemistry , computer science , programming language
BACKGROUND Previous studies have shown that beta‐microseminoprotein (β‐MSP) may be used as a diagnostic marker for prostate cancer. However, the level of expression of β‐MSP in prostate cancer detected by immunohistochemistry (IHC) has varied from one study to another. METHODS We analyzed the expression of both β‐MSP mRNA and its protein in a large sample of prostate tumors from 104 patients with untreated prostate cancer, using both nonradioactive in situ hybridization (ISH) and IHC. RESULTS Our results showed that 72 and 96 of 104 specimens were negative for β‐MSP mRNA (69.2%) and β‐MSP (92.3%), respectively. Furthermore, a reduced expression of both β‐MSP mRNA and its protein was detected in all malignant epithelial tissues compared with benign epithelia. Not all malignant tissue samples negative for β‐MSP mRNA were negative for β‐MSP (6.7%), and vice versa (29.8%). Other tissue samples were either negative for both (62.5%) or positive for both (1.0%). CONCLUSIONS Our results showed a lower level of expression of β‐MSP in prostate cancer tissue, compared with benign prostate tissue. This phenomenon may be mainly due to the presence of reduced levels of β‐MSP mRNA. Prostate 35:109–116, 1998. © 1998 Wiley‐Liss, Inc.